Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precipio Inc PRPO

Healthcare
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through... see more

Recent & Breaking News (NDAQ:PRPO)

Precipio and H3 Biomedicine Sign Second Development Agreement

GlobeNewswire June 25, 2019

Precipio CEO Provides Update Letter To Shareholders

GlobeNewswire June 17, 2019

Precipio Signs Exclusive Manufacturing Agreement for IV-Cell(TM)

GlobeNewswire June 4, 2019

Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement in Q1-2019

GlobeNewswire May 30, 2019

Precipio CEO enrolls in long term stock purchase plan

GlobeNewswire May 23, 2019

Precipio Regains Nasdaq Listing Compliance

GlobeNewswire May 15, 2019

Precipio Conducts IV-Cell(TM) Validation Trial with a Prominent Laboratory

GlobeNewswire May 6, 2019

Precipio Successfully Completes Nasdaq Hearing Process

GlobeNewswire May 3, 2019

Precipio Reminder of Corporate Update Shareholder Call

GlobeNewswire May 1, 2019

Precipio Signs First Major International Services Contract

GlobeNewswire April 29, 2019

Precipio Takes Final Step towards Regaining Nasdaq Compliance

GlobeNewswire April 26, 2019

Precipio Launches Global Expansion Strategy

GlobeNewswire April 24, 2019

Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer

GlobeNewswire April 18, 2019

Precipio Announces 2018 Year-End Corporate Update Call for Shareholders

GlobeNewswire April 15, 2019

Precipio Identifies Manufacturer for its IV-Cell Media

GlobeNewswire April 9, 2019

Precipio’s HemeScreen™ Adopted by Methodist Health

GlobeNewswire April 3, 2019

Precipio Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

GlobeNewswire March 27, 2019

Precipio CEO Issues Shareholder Update Letter

GlobeNewswire March 11, 2019

Continued ICP Orders From Japanese Customers

GlobeNewswire March 5, 2019

Precipio Provides Corporate Update Shareholder Call

GlobeNewswire February 18, 2019